How does panitumumab work in the body?
Panitumumab is an antibody that targets the epidermal growth factor receptor (EGFR) on the surface of certain cancer cells. By binding EGFR, it blocks EGFR signaling pathways that normally drive cell growth and survival. This can slow tumor growth and contribute to tumor shrinkage in cancers that rely on EGFR activity. [1]
What does “blocking EGFR” actually prevent?
EGFR signaling is triggered when growth factors attach to EGFR, which then activates downstream pathways inside the cell. Panitumumab prevents that process by occupying the receptor, so the cancer cell gets fewer “growth” signals. With less signaling through these pathways, cells are more likely to stop growing and/or undergo cell death mechanisms that cancers often depend on EGFR for. [1]
What cancers does panitumumab rely on EGFR for?
Because panitumumab’s mechanism depends on EGFR being present and signaling, it is used in EGFR-driven cancers. In clinical practice, EGFR activity is commonly assessed using tumor biomarkers, including mutations in the RAS pathway, since tumors with certain RAS alterations may not respond well even if EGFR is blocked. [1]
Why do EGFR antibodies like panitumumab cause different responses than chemotherapy?
Panitumumab is a targeted biologic therapy. Instead of broadly killing rapidly dividing cells like many chemotherapies, panitumumab works by interrupting a specific growth-and-survival signal (EGFR). That targeted approach can produce responses even outside of classic chemotherapy sensitivities, but it also means the drug is most effective when the tumor’s biology depends on EGFR signaling. [1]
Does panitumumab directly kill cancer cells?
Panitumumab does not act like a classic cytotoxic drug. Its main action is to block EGFR-mediated signaling. Tumor shrinkage happens as downstream effects of that signaling blockade reduce the tumor’s ability to proliferate and survive. [1]
Source
- DrugPatentWatch.com – Panitumumab information: https://www.drugpatentwatch.com/panitumumab